BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31411343)

  • 1. Genomic characterisation of breast fibroepithelial lesions in an international cohort.
    Md Nasir ND; Ng CCY; Rajasegaran V; Wong SF; Liu W; Ng GXP; Lee JY; Guan P; Lim JQ; Thike AA; Koh VCY; Loke BN; Chang KTE; Gudi MA; Lian DWQ; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Tan P; Teh BT; Tan PH
    J Pathol; 2019 Dec; 249(4):447-460. PubMed ID: 31411343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
    Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
    Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
    J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of MED12 exon 2 in a spectrum of fibroepithelial tumours of the breast: implications for pathogenesis and histogenesis.
    Lien HC; Huang CS; Yang YW; Jeng YM
    Histopathology; 2016 Feb; 68(3):433-41. PubMed ID: 26109290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.
    Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH
    BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
    Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Chang HY; Koh VCY; Md Nasir ND; Ng CCY; Guan P; Thike AA; Teh BT; Tan PH
    J Clin Pathol; 2020 Jan; 73(1):51-56. PubMed ID: 31662438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast.
    Piscuoglio S; Murray M; Fusco N; Marchiò C; Loo FL; Martelotto LG; Schultheis AM; Akram M; Weigelt B; Brogi E; Reis-Filho JS
    Histopathology; 2015 Nov; 67(5):719-29. PubMed ID: 25855048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroepithelial lesions; The WHO spectrum.
    Krings G; Bean GR; Chen YY
    Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Profiling of Fibroepithelial Lesions of the Breast.
    Li X; Vail E; Maluf H; Chaum M; Leong M; Lownik J; Che M; Giuliano A; Cao D; Dadmanesh F
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.
    Tan BY; Md Nasir ND; Chang HY; Ng CCY; Guan P; Nagarajan S; Rajasegaran V; Lee JY; Lim JQ; Thike AA; Teh BT; Tan PH
    Mod Pathol; 2020 Sep; 33(9):1732-1745. PubMed ID: 32322022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent
    Pareja F; Da Cruz Paula A; Murray MP; Hoang T; Gularte-Mérida R; Brown D; da Silva EM; Sebastiao APM; Giri DD; Weigelt B; Reis-Filho JS; Brogi E
    J Clin Pathol; 2019 Mar; 72(3):258-262. PubMed ID: 30467240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.
    Garcia-Dios DA; Levi D; Shah V; Gillett C; Simpson MA; Hanby A; Tomlinson I; Sawyer EJ
    Br J Cancer; 2018 Jan; 118(2):277-284. PubMed ID: 29315289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor.
    Piscuoglio S; Geyer FC; Burke KA; Murray MP; Ng CK; Mota A; Marchio C; Berman SH; Norton L; Brogi E; Weigelt B; Reis-Filho JS
    NPJ Breast Cancer; 2016; 2():16035. PubMed ID: 28721388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscapes of breast fibroepithelial tumors.
    Tan J; Ong CK; Lim WK; Ng CC; Thike AA; Ng LM; Rajasegaran V; Myint SS; Nagarajan S; Thangaraju S; Dey S; Nasir ND; Wijaya GC; Lim JQ; Huang D; Li Z; Wong BH; Chan JY; McPherson JR; Cutcutache I; Poore G; Tay ST; Tan WJ; Putti TC; Ahmad BS; Iau P; Chan CW; Tang AP; Yong WS; Madhukumar P; Ho GH; Tan VK; Wong CY; Hartman M; Ong KW; Tan BK; Rozen SG; Tan P; Tan PH; Teh BT
    Nat Genet; 2015 Nov; 47(11):1341-5. PubMed ID: 26437033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
    Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
    Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroepithelial Lesions in the Breast of Adolescent Females: A Clinicopathological Study of 54 Cases.
    Ross DS; Giri DD; Akram MM; Catalano JP; Olcese C; Van Zee KJ; Brogi E
    Breast J; 2017 Mar; 23(2):182-192. PubMed ID: 28299887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
    Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
    Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.
    Meyer B; Stirzaker C; Ramkomuth S; Harvey K; Chan B; Lee CS; Karim R; Deng N; Avery-Kiejda KA; Scott RJ; Lakhani S; Fox S; Robbins E; Shin JS; Beith J; Gill A; Sioson L; Chan C; Krishnaswamy M; Cooper C; Warrier S; Mak C; Rasko JE; Bailey CG; Swarbrick A; Clark SJ; O'Toole S; Pidsley R
    J Pathol; 2024 Apr; 262(4):480-494. PubMed ID: 38300122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.